湿润烧伤膏灌肠治疗溃疡性直肠炎疗效观察

目的观察湿润烧伤膏(MEBO)保留灌肠治疗溃疡性直肠炎的临床疗效。方法将40例溃疡性直肠炎患者随机分为治疗组(20例)和对照组(20例)。治疗组采用湿润烧伤膏20 mL保留灌肠(每天1次)配合口服美沙拉嗪肠溶片(每次0.5 g,每天3次)治疗;对照组采用康复新液50 mL+0.9%氯化钠50 mL保留灌肠(每天1次)配合口服美沙拉嗪肠溶片(每次0.5 g,每天3次)治疗。观察、对比两种治疗方法的临床疗效。结果治疗组的临床综合疗效明显优于对照组,其中治疗组临床总体疗效的无效患者(1例)少于对照组(5例)(x~2=4.557,P0.05,差异有统计学意义);治疗组经治疗后,腹泻、腹痛、黏液脓血便、黏膜表现的积分明显少于治疗前(x~2=4.421,P0.05,差异有统计学意义);治疗组中医证候疗效的无效患者(2例)少于对照组(7例)(x~2=4.535,P0.05,差异有统计学意义);治疗组内镜下直肠黏膜表现的无效患者(2例)少于对照组(8例)(x~2=6.166,P0.05,差异有统计学意义)。两组患者的病情分级及疗效均存在正相关性。结论湿润烧伤膏能够改善溃疡性直肠炎患者的症状及体征,促进溃疡创面愈合,对轻、中度溃疡性直肠炎具有显著疗效。

Observation of Efficacy of Treating Ulcerative Proctitis with MEBO Enema

Objective To observe the cliniealefficacy of treating ulcerative proctitis by retention enema with MEBO. Methods 40 patients with ulcerative proetitis were randomly divided into a treatment group （20 eases） and a control group （20 cases）. The patients in the treatment group received retention enema with MEBO （20mL, once a day） and took mesalazine enteric-coated tablets （0. 5g/time, 3 times/clay）; the patients inthe control ground received the retention enema with Kangfuxin liquid （50 mL） ＋ 0. 9% sodium chloride （50 mL） （ once a day） and took mesalazine enteric-coated tablets （0.5g/time, 3 times/day）. Clinical efficacywasobserved and compared between the two methods. Results Clinical efficacy of the treatment group was better than that of the control group. Ineffective treatment in the treatment group （1 case） was less than that in the control group （5 eases） （x2= 4. 557, P 〈0. 05, the difference was statistically significant）. After treatment, diarrhea, abdominal pain and bloody mucopurulent stool in the treatment group were less （X2 = 4. 421, P 〈0. 05, and the difference was statistically significant） than that before treatment. Ineffective treatment of TCM in the treatment group （2 cases） was less than that in the control group （7 cases） （X2 =4. 535, P 〈0. 05, the difference was statistically significant） ; ineffective treatment of rectal mucosa revealed by endoscope in the treatment group （2 cases） was less than that in the control group （8 cases） （X2 = 6. 166, P 〈0. 05, the difference was statistically significant）. Disease classification and efficacy in the two groups were positively correlated. Conclusion MEBO can improve the symptoms and signs of patients with ulcerative proctitis, and stimulate recovery of ulcers. It has remarkable effect on mild and moderate ulcerative proctitis.